How do I read and understand my Multiple Myeloma pathology report

Understanding Your Multiple Myeloma Pathology Report

I'm glad you're taking an active role in understanding your diagnosis. A pathology report can feel overwhelming, but breaking it down into sections makes it much more manageable. Let me walk you through what you'll typically find and what it means.

What Is a Pathology Report?

A pathology report is a detailed analysis of tissue samples taken from your bone marrow. A pathologist (a doctor who specializes in examining cells and tissues under a microscope) examines your samples and documents what they find. According to the NCCN Guidelines for Patients: Multiple Myeloma, this report is essential because it confirms your diagnosis and helps your care team plan your treatment.

The Main Sections You'll See

1. Specimen Information

This section describes what was biopsied—usually bone marrow from your pelvic bone (near your hip). You'll see:

• Type of sample: Bone marrow biopsy and/or aspiration
• Location: Usually the pelvic bone
• Date collected: When the sample was taken

What it means: This just confirms what tissue was examined and where it came from.

---

2. Diagnosis/Clinical Impression

This is the most important section. It will state whether you have multiple myeloma and may include:

Key finding: "At least 10% of cells in the bone marrow sample are abnormal plasma cells"

According to NCCN Guidelines, a diagnosis of multiple myeloma requires that at least 10% (1 out of every 10 cells) of the bone marrow cells are abnormal plasma cells. If your report shows this, it confirms the diagnosis.

What it means: Your normal plasma cells (white blood cells that fight infection) have turned into myeloma cells that multiply uncontrollably and crowd out healthy blood cells.

---

3. Immunohistochemistry (IHC) Results

This test uses special stains to identify the number and type of myeloma cells in your bone marrow.

What you might see:

• Percentage of plasma cells (e.g., "25% plasma cells")
• Markers like CD138, CD38, or other proteins on the surface of myeloma cells
• Whether cells are "clonal" (all the same type—which indicates cancer)

What it means: These markers help confirm it's myeloma and not another condition. The higher the percentage of abnormal plasma cells, the more advanced your disease.

---

4. Flow Cytometry

This test identifies abnormal plasma cells by detecting specific proteins on their surface.

What you might see:

• Percentages of different cell types
• Notation of "abnormal plasma cell population" or "clonal population"
• Markers like CD19, CD38, CD138

What it means: Flow cytometry isn't always done at diagnosis—it might be done after treatment to check for remaining myeloma cells. It's another way to confirm the diagnosis and monitor treatment response.

---

5. FISH (Fluorescence In Situ Hybridization) Results

This is a critical test that looks for abnormal changes in the chromosomes of your myeloma cells. According to NCCN Guidelines, this helps determine whether your myeloma might be high-risk (more likely to come back quickly) or standard-risk.

What you might see:

• Deletions: Loss of part of a chromosome (e.g., "deletion 13" or "del 17p")
• Translocations: Parts of chromosomes swapping places (e.g., "t(4;14)" or "t(14;16)")
• Amplifications: Extra copies of genes (e.g., "1q21 amplification")
• Normal: No abnormal changes detected

What it means:

• Deletion of chromosome 17 (del 17p): High-risk—associated with more aggressive myeloma
• Translocation t(4;14) or t(14;16): High-risk
• 1q21 amplification: Associated with more aggressive disease
• No abnormalities: Standard-risk (generally better prognosis)

Important: Having 2 or more high-risk features means "very high-risk" myeloma, which may require more intensive treatment.

---

6. Cytogenetics

This section reports on the overall chromosome structure of your myeloma cells.

What you might see:

• Chromosome count (normal is 46; myeloma cells often have abnormal numbers)
• Specific chromosome abnormalities

What it means: Helps your doctor understand how aggressive your myeloma is and plan treatment accordingly.

---

Understanding Your M Protein Type

Your pathology report should also tell you your M protein subtype. According to NCCN Guidelines, this is important because it helps you track your disease response to treatment.

Common types:

• IgG kappa
• IgG lambda
• IgA kappa
• IgA lambda
• Light chain only (kappa or lambda)

What it means: Your myeloma cells produce one specific type of abnormal antibody. You can follow your M protein level in blood tests to see if it's decreasing (good response), stable, or increasing (disease progression).

---

What to Look For: Key Questions

When reading your report, ask yourself:

1. Is myeloma confirmed? (Look for ≥10% abnormal plasma cells)
2. What's my M protein type? (Helps track treatment response)
3. What are my FISH results? (Determines risk level and treatment intensity)
4. Are there any other abnormalities? (Helps predict how aggressive the disease is)

---

Questions to Ask Your Oncologist

• "Can you explain my FISH results and what they mean for my prognosis?"
• "What is my M protein type, and how will we track it during treatment?"
• "Based on my pathology findings, am I considered standard-risk or high-risk myeloma?"
• "Are there any other findings in my pathology report that affect my treatment plan?"
• "Will my pathology tissue be saved for additional testing if needed?"
• "Should I get a second opinion on my pathology results?"

---

Important Context

According to NCCN Guidelines, your pathology report is just one piece of the puzzle. Your care team will also use:

• Blood tests (M protein levels, free light chains, immunoglobulin levels)
• Imaging (PET/CT, MRI, or bone surveys)
• Your symptoms and overall health

All of this information together helps your doctor determine your disease stage and create your personalized treatment plan.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.